SIRT2
医学
生物标志物
肌萎缩侧索硬化
疾病
肿瘤科
内科学
认知
多发性硬化
痴呆
认知功能衰退
生物信息学
临床疾病
中枢神经系统疾病
认知障碍
神经科学
免疫学
退行性疾病
认知障碍
病理
病态的
病理生理学
治疗方法
作者
Jun Zhu,Tianrui Wen,Ninglu Gao,Bin Wu,Mingjie Ma,Xiaohan Sun,Fuchen Liu,Pengfei Lin,Shuangwu Liu
摘要
ABSTRACT Introduction/Aims Amyotrophic lateral sclerosis (ALS) lacks reliable biomarkers to predict disease trajectories or guide therapeutic strategies. Sirtuin 2 (SIRT2), a NAD+‐dependent deacetylase implicated in cytoskeletal destabilization and neuroinflammatory pathways in preclinical ALS models, represents a promising yet unvalidated biomarker candidate. We aimed to translate preclinical findings by validating SIRT2's role in ALS. Methods A cross‐sectional cohort study was conducted, comparing serum SIRT2 levels, measured via enzyme‐linked immunosorbent assay (ELISA), between 182 ALS patients and 65 healthy controls. Clinical progression rates were derived from the ALS Functional Rating Scale‐Revised (ALSFRS‐R), and cognitive function was assessed using the Mini–Mental State Examination (MMSE) and Edinburgh Cognitive and Behavioral ALS Screen (ECAS). Results SIRT2 levels were significantly elevated in ALS patients versus controls, though diagnostic accuracy was modest (AUC = 0.620). Furthermore, SIRT2 levels showed a weak but significant positive correlation with disease progression rate ( r = 0.182, p = 0.014) and inverse correlations with cognitive scores on both MMSE ( r = −0.250, p = 0.032) and ECAS ( r = −0.286, p = 0.031). Notably, SIRT2 demonstrated a limited but detectable ability to stratify patients into fast‐ and slow‐progressing subgroups (AUC = 0.635). Discussion These findings provide preliminary clinical evidence linking elevated serum SIRT2 to disease progression and cognitive impairment in ALS, thereby supporting its role in disease heterogeneity. This work lends clinical support to preclinical insights, suggesting SIRT2 may aid in prognosis prediction and may represent a potential therapeutic target, necessitating further studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI